A Phase 2/3 Study of S-524101 in the Patients with Perennial Allergic Rhinitis

Trial Profile

A Phase 2/3 Study of S-524101 in the Patients with Perennial Allergic Rhinitis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 30 Mar 2015 Based on data from this study, Shionogi has received the approval of S-524101 [STG320] from the Japanese health authorities (PMDA - Pharmaceuticals and Medical Devices Agency), according to a Stallergenes SA media release; it is the first immunotherapy tablet registered in Japan for the treatment of house dust mite-induced allergic rhinitis.
    • 13 Feb 2014 New trial record
    • 03 Feb 2014 Status changed from active, no longer recruiting to completed, according to a Stallergenes SA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top